

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

Assignment ID: PATI153613

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	ASSIGNMENT	
CONVEYING PARTY DATA		
	Name	Execution Date
	CURIA GLOBAL, INC.	05/05/2023
RECEIVING PARTY DATA		
Company Name:	ACTINIUM PHARMACEUTICALS, INC.	
Street Address:	100 PARK AVENUE, 23RD FLOOR	
City:	New York	
State/Country:	NEW YORK	
Postal Code:	10017	
PROPERTY NUMBERS Total: 1		
Property Type	Number	
Application Number:	18464847	
CORRESPONDENCE DATA		
Fax Number:		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
Phone:	4122974900	
Email:	ippatent.dcg@dentons.com	
Correspondent Name:	Angela Heukeshoven	
Address Line 1:	625 Liberty Avenue	
Address Line 2:	Dentons Cohen & Grigsby P.C.	
Address Line 4:	Pittsburgh, PENNSYLVANIA 15222	
ATTORNEY DOCKET NUMBER:	PT23-025 PCT-1/CIP	
NAME OF SUBMITTER:	ANGELA HEUKESHOVEN	
SIGNATURE:	ANGELA HEUKESHOVEN	
DATE SIGNED:	04/09/2024	
Total Attachments: 3		
source=ATNM-016_Confirmatory_Assignment_(Curia_Global_Inc_to_Actinium)_Fully_Executed#page1.tif		
source=ATNM-016_Confirmatory_Assignment_(Curia_Global_Inc_to_Actinium)_Fully_Executed#page2.tif		
source=ATNM-016_Confirmatory_Assignment_(Curia_Global_Inc_to_Actinium)_Fully_Executed#page3.tif		

CONFIRMATORY ASSIGNMENT

The Applications

Patent Application No.	Filing Date	Title
U.S. 63/323,257	March 24, 2022	HUMANIZED ANTI-CD45 ANTIBODIES
U.S. 63/405,237	September 9, 2022	HUMANIZED ANTI-CD45 ANTIBODIES
U.S. 63/407,979	September 19, 2022	HUMANIZED ANTI-CD45 ANTIBODIES
PCT/US2023/064941	March 24, 2023	HUMANIZED ANTI-CD45 ANTIBODIES

The Reports

By	For	Title
LakePharma, Inc.	Actinium Pharmaceuticals, Inc.	SR-21479 Humanization of (1) mIgG with Octet against (1) antigen - Actinium Pharma <i>T20 Humanness Interim Update</i>
LakePharma, Inc.	Actinium Pharmaceuticals, Inc.	SR-21479 & SR-21480 Humanization of (1) mIgG with Octet against (1) antigen - Actinium Pharma <i>Project Report with Processed Affinity Measurement Data</i>

WHEREAS, Dr. Lequn Zhao (hereafter "Inventor") is an inventor of certain new and useful inventions as set forth and disclosed in the above-referenced Applications and Reports (hereafter the "Inventions");

WHEREAS, Inventor previously conveyed to LakePharma, Inc., a corporation organized under the laws of the State of California (USA) and having a place of business at 530 Harbor Blvd., Belmont, CA 94002 USA (hereafter "LakePharma") all of Inventor's rights, title, and interest in and to the Inventions pursuant to Inventor's obligations as an employee of LakePharma;

WHEREAS, the Inventions were made for the benefit of Actinium Pharmaceuticals, Inc., a corporation organized under the laws of the State of Delaware (USA) and having a place of business at 100 Park Avenue, 23rd Floor, New York, New York 10017 USA (hereafter "Assignee") in connection with LakePharma providing antibody humanization services to Assignee;

WHEREAS, LakePharma was obligated to assign and did assign to Assignee all rights, title and interest in and to the Inventions;

WHEREAS, LakePharma, Inc. was subsequently acquired by Curia Global, Inc., a corporation organized under the laws of the State of Delaware (USA) and having a place of business at 26 Corporate Circle, Albany, New York 12203 USA (hereafter "Assignor");

WHEREAS, as a result of the acquisition of LakePharma by Assignor, all of LakePharma's rights, title and interest in and to the Inventions that may have remained in LakePharma were transferred to

Assignor:

WHEREAS, Assignor and Assignee wish to confirm the full and complete transfer of all of Assignor's rights, title and interest in and to the Inventions to Assignee, including any rights, title or interest that, for any reason whatsoever, may not have been previously transferred to Assignee;

NOW, THEREFORE, pursuant to the obligations of assignment set forth hereinabove and in consideration of and in exchange for the sum of ONE UNITED STATES DOLLAR (US \$1.00) and other good and valuable consideration, the receipt and sufficiency thereof being hereby acknowledged, Assignor hereby sells or has sold, assigns or has assigned, and otherwise transfers or has transferred to Assignee, its successors, legal representatives, and assigns, their entire worldwide right, title, and interest in and to the Inventions, the Applications, and any and all other patent applications and patents for the Inventions which may be applied for or granted therefor in the United States and in all foreign countries and jurisdictions, including all divisions, continuations, continuations-in-part, reissues, reexaminations, renewals, restorations, extensions, counterparts, substitutes, and extensions thereof, and all rights of priority resulting from the filing of such applications and granting of such patents. Assignor agrees that, if the data above regarding one or more of the Applications is incomplete, the missing data may be added hereto after receipt of the same from the patent office in which the Application is filed.

IN ADDITION, Assignor hereby authorizes and requests the Director of the United States Patent and Trademark Office to issue any United States Patent, and foreign patent authorities to issue any foreign patent, granted for the Inventions, to Assignee, its successors, legal representatives, and assigns, the entire worldwide right, title, and interest in and to the same to be held and enjoyed by Assignee, its successors, legal representatives, and assigns to the full end of the terms for which any and all such patents may be granted, as fully and entirely as would have been held and enjoyed by the Assignor had this Assignment not been made; and Assignor agrees to execute any and all documents and instruments and perform all lawful acts reasonably related to recording this Assignment or perfecting title to the Inventions and all related patents and applications, to Assignee, its successors, legal representatives, and assigns, whenever requested by Assignee, its successors, legal representatives, or assigns.

Assignor acknowledges their prior and ongoing obligations to sell, assign, and transfer the rights under this Assignment to Assignee and is unaware of any reason why they may not have the full and unencumbered right to sell, assign, and transfer the rights hereby sold, assigned, and transferred, and has not executed, and will not execute, any document or instrument in conflict herewith. Assignor also hereby grants Assignee, its successors, legal representatives, and assigns, the right to insert in this Assignment any further identification (including, but not limited to, Patent Application Numbers) which may be necessary or desirable for recordation of this Assignment.


[signature page follows]

IN WITNESS WHEREOF, Assignor and Assignee have executed this Confirmatory Assignment by the authorized signatures set forth below:

ASSIGNOR: Curia Global, Inc.

By: *Bon Miller* Date: *5/5/2023*
Name: *Bon Miller*
Title: *Senior Counsel, Intellectual Property*
Curia Global, Inc.

ASSIGNEE: Actinium Pharmaceuticals, Inc.

By:  Date: May 11, 2023
Name: Paul Diamond, Ph.D., Esq.
Title: Vice President, Patent and Legal Counsel
Actinium Pharmaceuticals, Inc.